Introduction: The diabetic foot (DF) is a complication with high rate of morbi-mortality. There are no data about amputation rates and mortality in Argentina related to this disease. The aim of this study was to describe clinical features of adult patients with diabetes that consulted for a foot ulcer in a 3 months' period and to evaluate outcomes six months later.
Methods: This is a multicenter longitudinal study with six months follow up.
Results: Three hundred and twelve patients from 15 health centers in Argentina were analyzed. During the follow up, the rate of major amputation was 8.33% (IC95; 5.5-11.9) (n = 26) and minor amputation 29.17% (IC95%; 24.2-34.6) (n = 91). After six months, the mortality rate was 4.49% (IC95%; 2.5-7.4) (n = 14), and 24.3% (IC95%; 19.6-29.5) remained with open wounds (n = 76) while 58.0% (IC95%; 52.3-66.5) (n = 181) healed and 7.37% became lost to follow up (n = 23). From those who required a major amputation during the study (n = 24), 5 patients died (20.8%) and in patients without amputation, 3% died (p = 0.001). Major amputation was related to age, ankle brachial index (ABI), Saint Elian score (SEWSS), SINBAD, WIfI classification, ischemia and some aspects of the wound.
Discussion: Knowledge about local data will enable better decisions on health policies related to prevention and treatment of diabetic foot patients.
Download full-text PDF |
Source |
---|
Cureus
December 2024
Trauma and Orthopaedics, Gateshead Health National Health Services (NHS) Foundation Trust, Gateshead, GBR.
Introduction Diabetes is a rapidly growing global health concern, with the World Health Organization (WHO) estimating that 300 million adults will have diabetes by 2025. This chronic condition is associated with complications, including nephropathy, retinopathy, neuropathy, cardiovascular disease, and diabetic foot ulcers (DFUs), which can lead to amputation. Diabetic septic foot (DSF), a severe form of diabetic foot disease, is defined by the WHO as the presence of infection, ulceration, or tissue destruction in the lower limb, often accompanied by neurological abnormalities, peripheral vascular disease, and metabolic complications of diabetes.
View Article and Find Full Text PDFSmall
January 2025
Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Road, Jiangning, Nanjing, 210009, China.
Infections caused by persistent, drug-resistant bacteria pose significant challenges in inflammation treatment, often leading to severe morbidity and mortality. Herein, the photosensitizer rhodamine derivatives are selected as the light-trapping dye and the electron-rich substituent N-nitrosoaminophen as the nitric oxide (NO)-releasing component to develop a multifunctional (deep) red-light activatable NO photocage/photodynamic prodrug for efficient treatment of wounds and diabetic foot infections. The prodrug, RhB-NO-2 integrates antimicrobial photodynamic therapy (aPDT), NO sterilization, and NO-mediated anti-inflammatory properties within a small organic molecule and is capable of releasing NO and generating Reactive oxygen species (ROS) when exposed to (deep) red laser (660 nm).
View Article and Find Full Text PDFEndocr J
January 2025
Department of Vascular, Shijiazhuang Hospital of Traditional Chinese Medicine, Shijiazhuang 050011, China.
Nerve aberrations and vascular lesions in the distal lower limbs are the etiological factors for diabetic foot ulcers (DFUs). This study aimed to understand the regulatory mechanism of angiogenesis in patients with DFU by examining lncRNA, as well as to explore effective targets for diagnosing and treating DFU. The serum levels of A1BG-AS1 and miR-214-3p and the predictive power of A1BG-AS1 for DFU were determined by quantitative PCR and ROC analysis.
View Article and Find Full Text PDFDiabetology (Basel)
October 2024
Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Objectives: This study aims to examine the association between state Medicaid coverage of podiatry services and the outcomes of beneficiaries with new diabetic foot ulcers (DFUs).
Methods: Medicaid beneficiaries who developed a DFU between 2010 and 2015 were identified using the PearlDiver claims database. The states were categorized into covered states (CS) and non-covered states (NCS) based on podiatric coverage during the study period.
Open Forum Infect Dis
January 2025
Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!